United States Endoscopy Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

United States Endoscopy Devices Market Trends and Insights

Rising Prevalence of GI & Colorectal Cancers

Colorectal cancer produced 147,931 new U.S. cases in 2022, and the screening age now begins at 45.^{[1]National Institute of Diabetes and Digestive and Kidney Diseases, “Indications & Outcomes of Gastrointestinal Endoscopy,” niddk.nih.gov} The change expands eligibility by about 19 million adults. Evening and weekend colonoscopy sessions are therefore common, which pushes practices to purchase durable, flexible scopes and automated washers that process 8 to 10 cases a day. The National Cancer Institute dedicated USD 274 million to colorectal research in fiscal 2024, signaling bipartisan backing for early detection. These forces together lift demand across the endoscopy devices market.

Advances in HD & AI-Assisted Imaging Platforms

Fujifilm’s CAD EYE joined three FDA-cleared AI modules in January 2024 and raised adenoma-detection rates by 8-12 percentage points. CMS added CPT 0596T in January 2025, which reimburses USD 175 per colonoscopy that incorporates AI, offsetting the typical software license fee.^{[2]Centers for Medicare & Medicaid Services, “CY 2025 Physician Fee Schedule Final Rule,” cms.gov} Pentax launched a 4K tower in March 2024, offering twice the pixel count of HD, enabling physicians to confirm lesion margins more quickly. Bundled 4K-plus-AI systems cost USD 150,000-180,000, but hospitals justify the premium with fewer missed lesions and higher throughput. These upgrades accelerate the replacement cycle and expand the endoscopy devices market.

Outpatient Shift to Ambulatory Surgical Centers for Minimally Invasive Endoscopy

Medicare listed 6,153 certified ambulatory surgical centers in 2022, and endoscopy accounted for 38% of their caseload. CMS raised ASC reimbursement by nearly 3% for key GI codes in the 2025 rule. Private-equity chains expanded endoscopy capacity by double digits in 2024. Single-use bronchoscopes and ureteroscopes eliminate on-site sterilization, cutting overhead by up to USD 75,000 per room each year. These economies strengthen outpatient purchasing and raise overall equipment turnover in the endoscopy devices market.

Aging Population Driving Procedure Volumes

Adults aged 65 and older will top 73 million by 2030. This group experiences a 4.5-fold higher rate of GI disease and requires surveillance endoscopy every one to three years. Pulmonology demand also grows: 14.5 million Americans met lung-screening criteria in 2024, though fewer than 6% underwent the needed bronchoscopy follow-up. Medicare Advantage plans now waive copays for screening colonoscopies, which keeps procedure volumes rising. The demographic swell broadens the endoscopy devices market base for the next decade.

High Capital Cost of Robotic / 4K Platforms

Intuitive Surgical’s Ion robot lists at USD 500,000-1 million and reached only 382 U.S. installs by December 2024, representing roughly 6% hospital penetration. Medtronic’s Hugo system cuts entry cost to USD 350,000 but still demands annual service near USD 80,000, raising five-year ownership above USD 750,000. Rural sites relying on cost-based Medicare payment rarely recover these sums, and 68% deferred new endoscopy purchases in 2024. High sticker prices, therefore, cap uptake and trim overall momentum in the endoscopy devices market.

Stringent FDA Re-Processing Compliance

FDA guidance now requires culture surveillance and detailed logs for duodenoscope reprocessing, adding USD 15,000-25,000 per scope each year. AAMI ST91 pushes hospitals to install automated washers with traceability, costing USD 150,000-250,000 per suite.^{[3]Association for the Advancement of Medical Instrumentation, “AAMI ST91 Flexible Endoscope Processing 2025,” aami.org} In 2024, 11% of reprocessed ureteroscopes still failed culture tests despite adherence to the protocol. Compliance prompts many sites to consider disposables, yet the expense also slows full fleet renewal, creating a modest drag on the endoscopy devices market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Device Type: Flexible Scopes Retain Lead while Operative Systems Accelerate

Endoscopes accounted for 53.27% of the 2025 revenue in the endoscopy devices market, anchored by flexible models that navigate tortuous GI and pulmonary anatomy and deliver high-definition video. Rigid scopes remain essential for laparoscopy and arthroscopy, but occupy a smaller share. Endoscopic operative devices are projected to rise at a 7.32% CAGR, outpacing the overall market, as surgeons adopt integrated insufflation and irrigation consoles that maintain stable pneumoperitoneum and shorten operative time. Capsule systems, such as Medtronic’s PillCam Crohn’s, address small-bowel imaging but still account for less than 3% of endoscopy device market share for this device type. 

Visualization equipment is shifting from a one-time purchase to a lease model where providers pay a per-procedure fee that bundles 4K cameras and AI software updates. Standard-definition towers are being phased out, and major vendors now channel R&D into 4K and 8K prototypes. Accessories such as wound protectors show double-digit growth as single-incision techniques spread. Manual instruments remain profitable consumables; hospitals procure roughly 15-20 sets per suite each year to replace dull forceps and snares.

By Application: GI Dominates while Gynecology Surges

Gastrointestinal procedures commanded 44.73% of application revenue in 2025, supported by more than 15 million annual U.S. colonoscopies and robust upper GI surveillance, though growth moderates as screening compliance plateaus. Gynecology is the fastest-growing application, with a 7.69% CAGR, as office-based hysteroscopy expands for fibroid and polyp removal, backed by updated 2024 ACOG guidelines. Laparoscopic surgeries hold a mid-teens share, and adoption of robotic assistance continues to climb despite uncertain reimbursement parity.

Pulmonology benefits from lower lung-screen thresholds, with roughly 8% of low-dose CT findings requiring follow-up bronchoscopy. Urology advances as single-use ureteroscopes improve turnaround time, and Boston Scientific’s LithoVue reached 22% market share by 2024. ENT, neurology, and orthopedics remain smaller niches, yet chip-on-tip cameras and fluorescence imaging are gradually broadening their procedural mix.

By Usability: Reusables Dominate but Disposables Gain Ground

Reusable platforms accounted for 64.78% of 2025 sales in the endoscopy devices market. Hospitals keep scopes for five to seven years and pay annual service fees of USD 12,000-18,000 per unit. Single-use devices, however, are projected to grow at a 9.01% CAGR as infection-control mandates and total-cost-of-ownership analyses favor disposables in low-volume settings. Ambu shipped 1.2 million disposable bronchoscopes globally in 2024, with 58% of them landing in the United States. Boston Scientific’s Exalt D addresses the risk of elevator-channel contamination and had 340 U.S. installations by the end of 2024.

Total-cost-of-ownership studies show single-use scopes cost USD 150-300 per procedure, versus USD 2,500-4,000 annually to reprocess a reusable scope used 200 times, making disposables viable at 15-20 monthly cases. Sustainability remains unresolved: single-use scopes generate up to 2 kilograms of plastic waste per case, yet life-cycle studies that include autoclave energy are inconclusive.

By End-User: Hospitals Dominate while Specialty Clinics Accelerate

Hospitals captured 73.08% of 2025 spend, driven by complex procedures such as ERCP and therapeutic bronchoscopy, which require anesthesia backup and intensive care access. Specialty clinics are forecast to grow at an 11.01% CAGR because independent gastroenterology, urology, and pulmonology groups invest in office suites that promise same-day diagnosis. Ambulatory surgical centers, embedded within specialty-clinic figures, adopt cart-based endoscopy systems that cost 30% less than hospital towers.

A 2024 AUA survey showed 41% of office urologists had switched to single-use cystoscopes to avoid autoclave delays. Hospitals still hold advantages in high-risk cases and receive 40-60% higher reimbursement under the outpatient prospective payment schedule. Regulatory standards for emergency readiness add overhead to hospital suites yet support premium contracting that preserves their majority share of the endoscopy devices market.

Geography Analysis

Regional variations shape the U.S. endoscopy devices market. Sun Belt states such as Florida, Texas, and Arizona report the fastest growth in procedures, driven by retiree inflows and higher rates of GI disorders. Florida alone added 47 Medicare-certified ambulatory surgical centers in 2024, each privileging single-use scopes after a 2023 bronchoscope outbreak underscored infection risk.

California and New York face tighter capital budgets. Medi-Cal covers 14.5 million people and reimburses colonoscopies at 15-20% below Medicare, prompting practices to limit state-program volumes. At the same time, New York’s academic hospitals are adopting AI modules early; Massachusetts General Hospital raised adenoma-detection rates by 9.7 points after deploying Olympus’ EndoBRAIN in September 2024.

Midwest consolidation funnels complex endoscopy to urban hubs as many rural hospitals close suites or shift to outpatient-only models. The National Rural Health Association estimates 23% of rural counties lack a gastroenterologist and rely on capsule endoscopy read remotely to fill gaps. In the Pacific Northwest, extended producer responsibility laws create uncertainty about single-use device uptake.

Regulatory Landscape

Endoscopy devices in the United States are regulated by the US Food and Drug Administration (FDA), with many products routed through the 510(k) pathway under Class II controls. FDA classification activity has stayed active across GI and urology. The endoscopic pancreatic debridement device was classified into Class II with special controls (September 2024), the anchored esophageal sheath received a classification order (November 2025), and a final order in May 2026 required 510(k) premarket notification for endoscopic suturing devices used to alter gastric anatomy for weight loss.

Compliance requirements around manufacturing quality systems and reprocessing validation continue to shape purchasing and product design. In February 2026, FDA transitioned away from the Quality System Inspection Technique (QSIT) to a new inspection process for medical device manufacturing facilities, which increased the operational emphasis on inspection readiness. At the same time, FDA guidance on reprocessing validation and labeling, supported by healthcare infection-prevention bodies such as APIC and technical frameworks such as AAMI ST91, supports demand for traceability, documented cleaning instructions, and validated workflows for reusable scopes. This also influences adoption of single-use alternatives among facilities dealing with reprocessing audit pressure.

Market Opportunities and Future Outlook

Service and repair capacity for the installed base is emerging as a clear whitespace as providers push higher endoscopy throughput and replace towers with premium imaging bundles that include AI modules. In May 2026, FUJIFILM Healthcare Americas Corporation commenced operations at a new 18,000-square-foot endoscopy warehouse facility in Fairfield, New Jersey, expanding its US service-center capacity by about 1.5 times. This signals that turnaround time, loaner availability, and field service logistics are becoming competitive differentiators alongside imaging performance.

Regulatory standard-setting is also creating pathways for differentiated therapeutic and accessory devices that can demonstrate risk controls through defined test and design requirements. In June 2026, FDA published a final order establishing special controls for endoscopic traction devices, specifying non-clinical performance testing and design requirements for risks such as perforation, bleeding, and mucosal injury. For developers targeting procedure efficiency and safety in GI and related endoscopic interventions, the guidance adds specificity to evidence expectations. More broadly, the updated FDA inspection practices (February 2026) elevate the value of suppliers with mature quality systems, validated reprocessing instructions, and documentation that supports hospital and ASC audits.